Generic Formulations and API products are listed below.
CONTACT
Group Companies
GENERICS
GENERIC FORMULATIONS
| Sl. No | Molecule Name | Status |
| 1 | Rosuvastatin | Commercial (United States, Europe) |
| 2 | Simvastatin | Commercial (United States) |
| 3 | Atorvastatin | Commercial (United States) |
| 4 | Fingolimod | Approved (United States, Europe) |
| 5 | Dapagliflozin | Tentative Approval (United States) |
| 6 | Pemetrexed | Tentative Approval (United States) |
| 7 | Tacrolimus | Commercial (United States) |
| 8 | Everolimus (RLD Affinitor) | Commercial (United States), Approved (Europe) |
| 9 | Pravastatin | Commercial (United States) |
| 10 | Labetalol | Commercial (United States) |
| 11 | Esomeprazole | Commercial (United States) |
| 12 | Posaconazole | Commercial (United States) |
API
| Cardiology | |
| Sl. No | Molecule Name |
| 1 | Simvastatin |
| 2 | Pravastatin |
| 3 | Atorvastatin |
| 4 | Rosuvastatin |
| 5 | Fluvastatin |
| 6 | Dabigatran |
| 7 | Sacubitril/Valsartan |
| 8 | Apixaban |
| 9 | Rivaroxaban |
| Anti-Diabetics | |
| Sl. No | Molecule Name |
| 1 | Vildagliptin |
| 2 | Linagliptin |
| 3 | Sitagliptin (various salts) |
| 4 | Dapagliflozin (different solvate forms) |
| 5 | Empagliflozin |
| 6 | Repaglinide |
| 7 | Liraglutide |
| 8 | Semaglutide |
| Immunosuppressants | |
| Sl. No | Molecule Name |
| 1 | Tacrolimus |
| 2 | Sirolimus |
| 3 | Everolimus |
| 4 | Pimecrolimus |
| 5 | Mycophenolate Mofetil (MMF) |
| 6 | Mycophenolate Sodium (MPS) |
| Multiple Sclerosis | |
| Sl. No | Molecule Name |
| 1 | Glatiramer Acetate |
| 2 | Fingolimod |
| 3 | Teriflunomide |
| Anti-Cancer/Oncology | |
| Sl. No | Molecule Name |
| 1 | Dasatinib |
| 2 | Lenalidomide |
| 3 | Pazopanib |
| 4 | Erdafitinib |
| Other Key Products | |
| Sl. No | Molecule Name |
| 1 | Orlistat |
| 2 | Mirabegron |
| 3 | Posaconazole |
| 4 | Micafungin |
| 5 | Anidulafungin |
| 6 | Brinzolamide |
Know more
about us
KEY MANAGEMENT TEAM
PRESS RELEASES
OUR LEGACY
CORPORATE GOVERNANCE
